Prevention and treatment of osteoporosis with traditional herbal medicine

Current Topics in Osteoporosis

Volumn , Issue , 2005, Pages 513-531

  Qin, Ling ^a   Zhang, Ge ^a,b   Shi, Yenyu ^b   Lee, Kwongman ^a   Leung, Pingcheung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967468284     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812701220_0019     Document Type: Chapter

References (55)

1. Riggs BL, Melton LJ. The world-wide problem of osteoporosis: insights afforded by epidemiology. Bone 17:505-511, 1995.
2. Ramsey LA, Ross BS, Fischer RG. Phytoestrogens and the management of menopause. Adv Nurse Practitioners 7:26-30,1999.
3. Lien LL, Lien EJ. Hormone therapy and phytoestrogens. J Clin Pharm Therap 21(2):101-111, 1996.
4. Cohen DP. Anti-Osteoporotic Medications: Traditional and nontraditional. Clin Obst Gynecol 46(2):341-348, 2003.
5. Prestwood KM. Editorial: The search for alternative therapies for menopausal women: Estrogenic effects of herbs. J Clin Endocrinol Metabol 88(9):4075-4076, 2003.
6. Qin L. R&D of Herbal Formulae for Prevention and Treatment of Osteoporosis. Proceedings pp 112-120, 2002 International Bone Research Instructional Course and Hands-on Workshop, Hong Kong, October 17-19, 2002.
7. Qin L, Zhang G, Hung WY, Dambacher MA, Leung PC. Phytoestrogen-rich herbal formula for prevention of OVX induced bone loss in rats. J Bone Miner Res 17(suppl-1):479, 2002.
8. Han LM, Liu Bo, Xu P. Influence of herba epimedii flavone on proliferation of osteoblasts. Shanghai J Trad Chin Med 37(6):55-57, 2003.
9. Guo BL. Contents and prospects of resource of herba epimedii flavone in China. J Chin Med Mater 16(9): 13-14, 1993.
10. Yin J, Guo L (eds). Modern Study and Clinical Applications on Chinese Materia Medica. Xue Yuan Press, Beijing, pp 382-652, 1993.
11. Zhang DX, Jiang TY, Wang LL, et al. Effect of Xianlinggubao tablet on bone pain resutlt from osteoporosis. Chin J Rehab Theo Prac 7(2):84-85, 2001.
12. An SJ. Effect of kidney-tonifying herbs on ovary function and bone mass in postmenopausal women. Chin J Osteoporosis 6(2):55-59, 2000.
13. Li QF, Tan ZH, Xie XQ, et al. The effects of traditional bone tonifying prescription on pain and bone density in patients with osteoporosis. Chin J Clin Rehab 7(11): 1666-1667, 2003.
14. Shi YY et al. Comparative study of four Chinese formulas on prevention of osteoporosis. Chin J Osteoporosis. 4(3):68-70, 1998.
15. Shi YY. Summary report on Xianlingubao capsule for treatment of osteoporosis -clinical investigations. Int J Chin Orthop 2(2):18-21, 2000.
16. Cheng J, Lee P, Li J, Dennehy CE, Tsourounis C. Use of Chinese herbal products in Oakland and San Francisco Chinatowns. Am J Health-System Pharma 61(7):688-694, 2004.
17. Hidaka S, Okamoto Y, Nakajima K, Suekawa M, Liu SY. Preventive effects of traditional Chinese (Kampo) medicines on experimental osteoporosis induced by ovariectomy in rats. Calcif Tissue Int 61(3):239-246,1997.
18. Hidaka S, Okamoto Y, Yamada Y, Kon Y, Kimura T, A Japanese herbal medicine, Chujo-to, has a beneficial effect on osteoporosis in rats. Phytother Res 13(1):14-19, 1999.
19. Sakamoto S, Sassa S, Kudo H, Suzuki S, Mitamura T, Shinoda H. Preventive effects of a herbal medicine on bone loss in rats treated with a GnRH agonist. Euro J Endocrinol 143(1):139-42, 2000.
20. Sassa S, Sakamoto S, Zhou YF, Mori T, Kikuchi T, Shinoda H. Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats. In Vivo 15(1): 25-8, 2001.
21. Kass-Annese B. Alternative therapies for menopause. Clin Obstet Gynecol 43(1): 162-183, 2000.
22. WHO 1998. World Health Organization. Regulatory situation of herbal medicines: a worldwide review. Geneva, World Health Organization, 1998.
23. WHO 2003: WHO Traditional Medicine Strategy 2002-2005: http://www.who.int/medicines/organization/trm/orgtrmmain.shtml. World Health Organization, 2003.
24. WHO 2000. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. Geneva, World Health Organization, 2000.
25. WHO 1998. World Health Organization. Quality control methods for medical plant materials. Geneva, World Health Organization, 1998.
26. Tang JL, Leung PC. An efficacy-driven approach to the research and development of traditional Chinese medicine. HK Med J 7(4):375-380, 2001.
27. Lewith GT, Breen A, Filshie J, Fisher P, Mclntyre M, Mathie R, Peters D. Complementary medicine: evidence base, competence to practice and regulation. Clin Med 3(3):235-240, 2003.
28. Qin L. Call for establishing international standards for research & development of herbal medicine in the prevention and treatment of osteoporosis. The 2nd HOMA Awarding Ceremony & 2003 International Osteoporosis Conf Proc pp 77-83, Beijing, October 19-22, 2003.
29. Qin L, Shi YY, Lu HB, Zhang G, Hung YW, Leung PC. Bone mineral density and structural evaluation on preventive effects Chinese herbal preparation in oariectomy-induced osteoporosis in rats. Internationa] Symposium on Bone Biotechnology and Histotechnology, Phoenix, Arizona, USA, Proceedings p 30, 2001.
30. Xiong XH, Liu QS, Yu KQ. Effects of GuKang on bone Gla-protein in serum and bone mineral density in the ovariectomized rats. Chin J Trad Med Traumatol Orthop 10(2): 14-16, 2002.
31. Cui SQ. Prevention and treatment of osteoporosis in rats induced by retinoic acid with Gushukang combined with calcium. Chin J Osteoporosis 5(2):74-77, 1999.
32. Wang CH, Wang W, Li JC. Clinical efficacy of Gusongkang capsule in treatment of postmenopausal osteoporosis. Chin J Osteoporosis 9(2):165-166,131,2003.
33. Xu M, Dick IM, Day R, Randall D, Prince RL. Effects of a herbal extract on the bone density, strength and markers of bone turnover of mature ovariectorriized rats. Am J Chin Med 31(1):87-101, 2003.
34. Frost HM. From Wolffs law to the Utah paradigm: insights about bone physiology and its clinical applications. Anat Rec 262(4):398-419, 2001.
35. Ferretti JL, Cointry GR, Capozza RF, Frost HM. Bone mass, bone strength, muscle-bone interactions, osteopenias and osteoporoses. Mechanisms Ageing Devel 124(3):269-79, 2003.
36. Qin L, Zhang Z, Hung WY, Shi YY, Leung PC, Leung KS. Phytoestrogen-rich herb formula ‘GB’ prevents OVX-induced deterioration of muscuoloskeletal tissues at hip in aged rats. The First Asian Pacific Congress of Bone Histomorphometry, Takamatsu, Japan, June 22-24, 2004.
37. Zhang Ge. Biomechanical Signaling Regulation and Control Systems: Interaction between Upper-stream muscle genes’ and down-stream bone materials, structure and strength" PhD thesis, Shanghai University of Chinese Medicine, China, 2003.
38. Cui JP. Effects of kidney-tonifying traditional Chinese drugs on activities of protein kinase C and Ca2+ -Mg2+ -ATPase in erythrocyte membrane. Chin J Osteoporosis 3(3):66-69, 1997.
39. Xu RH. Histochemical study on effect of Radix Savial Miltorrhizae on growth of isolated cells from embryonic chicken frontal bone cultured in vitro. Chin J Traditional Western Med 11(11):668-670, 1991.
40. Li H, Miyahara T, Tezuka Y, Namba T, Nemoto N, Tonami S, Seto H, Tada T, Kadota S. The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol Pharma Bulletin 21 (12): 1322-1326, 1998.
41. Jin WF, Wang HF, Wei DL, Zhao YF, Shi YY. Comparative study among several Chinese herbals for proliferation of osteoblasts and mineralization - an in vitro model. Symposium on Prevention of Osteoporosis in Elderly, Proc. pp 17-21, Ximan, China 2000.
42. Lin YP. The effect of experimental fracture healing treated by Bu GU Su -Observation on osteoblast RNA an studies on blood biochemistry. Chin J Orthop Trauma 6(1):8-11, 1993.
43. Yu S, Chen K, Li S, Zhang K. In vitro and in vivo studies of the effect of a Chinese herb medicine on osteoclastic bone resorption. Chin J Dental Res 2(1):7-11, 1999.
44. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials. Ann Int Med 137(10):805-813, 2002.
45. Shi YY. Application of Chinese herbs to primary osteoporosis: Comprehensively improving the bone quality. 2002 International Bone Research Instructional Course and Hands-on Workshop. Proc. pp 104-111, Hong Kong, October 17-19, 2002.
46. Xu M. Treatment and prevention of postmenopausal osteoporosis with Chinese herbs. Doctoral thesis, The University of Western Australia, 2000.
47. Albrand G. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study. Bone. 32(1):78-85, 2003.
48. WHO 1998. Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva; 1998.
49. NIH: NIH statement on Osteoporosis Prevention, Diagnosis, and Therapy can be accessed on http://consensus.nih.gov/cons/cons.htm.
50. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 104(2): 170-178, 1998.
51. Qin L, Shi YY. Establishing international standards for research & development of herbal medicine in the prevention and treatment of osteoporosis. Chin J Osteoporosis 10(3): 2004 (in print).
52. Zhen XY. Guideline for New Drug R & D of Chinese herb. Science & Technology Publishing company of Chinese Medicamentc 2002.
53. Bureau of the Chinese State Food and Drug Administration. Administration for R & D of New Drugs, 2002.
54. Qin L, Yeung HY, Zhang M. State-of the Art technologies for bone and mineral research. Proc. p 62-64, 2nd Int Con. On Bone and Mineral Research & 4th Int Osteoporosis Symposium & First WHO-Collaborating Center Asian Regional Conf on Osteoporosis. Guilin, China, March 26-31, 2004.
55. The Writing Group for the ISCD Position Development Conference. Position statement: introduction, methods, and participants. The Writing Group for the International Society for Clinical Densitometry (ISCD) Position Development Conference. J Clin Densitometry. 7(1):13-6, 2004.